Sana Biotechnology, Inc. (SANA) Financial Statements (2025 and earlier)

Company Profile

Business Address 188 EAST BLAINE STREET, SUITE 400
SEATTLE, WA 98102
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments104,701,000152,497,000199,007,000251,643,000311,082,000205,195,000
Cash and cash equivalent96,131,000127,566,000126,996,000134,958,000177,054,000133,517,000
Short-term investments8,570,00024,931,00072,011,000116,685,000134,028,00071,678,000
Restricted cash and investments4,195,0003,832,0003,832,0003,832,0003,832,0003,832,000
Other undisclosed current assets3,835,0004,479,0007,310,0007,978,0006,349,0004,488,000
Total current assets:112,731,000160,808,000210,149,000263,453,000321,263,000213,515,000
Noncurrent Assets
Operating lease, right-of-use asset54,837,00057,961,00061,040,00063,154,00071,565,00074,903,000
Property, plant and equipment73,687,00077,308,00082,826,00085,909,00081,649,00070,689,000
Intangible assets, net (including goodwill)199,822,000199,822,000199,822,000199,822,000199,822,000199,822,000
Goodwill140,627,000140,627,000140,627,000140,627,000140,627,000140,627,000
Intangible assets, net (excluding goodwill)59,195,00059,195,00059,195,00059,195,00059,195,00059,195,000
Other noncurrent assets4,393,0005,121,0005,555,0006,329,0007,078,0006,370,000
Total noncurrent assets:332,739,000340,212,000349,243,000355,214,000360,114,000351,784,000
TOTAL ASSETS:445,470,000501,020,000559,392,000618,667,000681,377,000565,299,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,197,00022,406,00026,471,00023,897,00024,932,00031,982,000
Accounts payable989,0005,210,0002,991,0003,817,0006,095,0004,108,000
Accrued liabilities12,208,00017,196,00023,480,00020,080,00018,837,00027,874,000
Other undisclosed current liabilities19,959,00023,027,00020,533,00026,792,00027,969,00032,505,000
Total current liabilities:33,156,00045,433,00047,004,00050,689,00052,901,00064,487,000
Noncurrent Liabilities
Liabilities, other than long-term debt198,586,000200,527,000204,795,000207,482,000207,912,000200,507,000
Other liabilities9,443,0009,896,0007,456,0007,302,000  
Operating lease, liability78,311,00081,663,00085,483,00088,559,00092,922,00090,901,000
Business combination, contingent consideration, liability110,832,000108,968,000111,856,000111,621,000114,990,000109,606,000
Other undisclosed noncurrent liabilities4,649,0004,556,00015,115,00020,847,00045,422,00012,799,000
Total noncurrent liabilities:203,235,000205,083,000219,910,000228,329,000253,334,000213,306,000
Total liabilities:236,391,000250,516,000266,914,000279,018,000306,235,000277,793,000
Equity
Equity, attributable to parent209,079,000250,504,000292,478,000339,649,000375,142,000287,506,000
Common stock23,00022,00022,00022,00022,00020,000
Additional paid in capital1,863,295,0001,855,318,0001,848,183,0001,835,503,0001,820,701,0001,625,637,000
Accumulated other comprehensive income (loss)  14,00054,000(19,000)(15,000)(60,000)
Accumulated deficit(1,654,239,000)(1,604,850,000)(1,555,781,000)(1,495,857,000)(1,445,566,000)(1,338,091,000)
Total equity:209,079,000250,504,000292,478,000339,649,000375,142,000287,506,000
TOTAL LIABILITIES AND EQUITY:445,470,000501,020,000559,392,000618,667,000681,377,000565,299,000

Income Statement (P&L) (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Operating expenses(50,630,000)(50,866,000)(61,761,000)(49,372,000)(110,724,000)(90,619,000)
Operating loss:(50,630,000)(50,866,000)(61,761,000)(49,372,000)(110,724,000)(90,619,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
249,000141,000(742,000)(4,121,000)215,000(224,000)
Loss from continuing operations:(50,381,000)(50,725,000)(62,503,000)(53,493,000)(110,509,000)(90,843,000)
Other undisclosed net income 992,0001,656,000  3,034,0002,726,000
Net loss:(49,389,000)(49,069,000)(62,503,000)(53,493,000)(107,475,000)(88,117,000)
Other undisclosed net income attributable to parent  2,579,0003,202,000  
Net loss available to common stockholders, diluted:(49,389,000)(49,069,000)(59,924,000)(50,291,000)(107,475,000)(88,117,000)

Comprehensive Income (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Net loss:(49,389,000)(49,069,000)(62,503,000)(53,493,000)(107,475,000)(88,117,000)
Comprehensive loss:(49,389,000)(49,069,000)(62,503,000)(53,493,000)(107,475,000)(88,117,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(14,000)(40,000)2,652,0003,198,00045,000142,000
Comprehensive loss, net of tax, attributable to parent:(49,403,000)(49,109,000)(59,851,000)(50,295,000)(107,430,000)(87,975,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: